Kerry’s Meeting With Syrian Opposition at Risk

Pool photo by Jacquelyn Martin

Secretary of State John Kerry spoke to reporters on the way to London on Sunday. Mr. Kerry has said that he has new ideas on how to force President Bashar al-Assad from power in Syria.

Mr. Kerry and foreign ministers from Europe and the Middle East are scheduled to meet in Rome on Thursday with opponents of President Bashar al-Assad of Syria, including Sheik Ahmad Moaz al-Khatib, who leads the opposition. But they are threatening to boycott the conference to protest what they see as fainthearted international support.

To try to rescue the meeting, Robert S. Ford, the American ambassador to Syria and chief envoy to the opposition, was sent to Cairo on Sunday to implore opposition leaders to attend the session in Rome.

“The Syrian opposition leadership is under severe pressure now from its membership, from the Syrian people, to get more support from the international community,” said a senior administration official who was traveling on Mr. Kerry’s plane. “And in that context, there’s quite a bit of internal discussion about the value of going in international conferences.”

The issue upset the first day of a carefully choreographed trip that is intended to introduce Mr. Kerry as the chief American envoy and to give a lift to the diplomatic stalemate on Syria. Mr. Kerry, who took office this month, is traveling to Britain, Germany, France, Italy, Turkey, Egypt, Saudi Arabia, the United Arab Emirates and Qatar over 11 days.

Even before his trip was formally announced, Mr. Kerry raised expectations by saying he had new ideas on how to change Mr. Assad’s calculations that he could remain in power.

Mr. Kerry has not publicly explained the proposals, but they appear to include marshaling support from Russia, which has been providing arms and financial help to Mr. Assad. Toward that end, Mr. Kerry plans to meet in Berlin on Wednesday with Sergey V. Lavrov, Russia’s foreign minister.

The meeting with the Syrian opposition is to be hosted by Italy. Last week, the European Union agreed to extend its embargo on weapons shipments to Syria for another three months, a move that precludes European arms shipments to the opposition.

But the European Union did agree to a British proposal that nonlethal assistance be expanded. As a result, body armor, night-vision goggles, armored vehicles and other equipment can be sent to armed opposition groups in Syria, an American official said.

So far, the Obama administration has not gone that far in its support. While the United States provides nonlethal assistance like computers and radios to the opposition, it has not been willing to provide nonlethal aid to armed factions within Syria, an approach that experts say has limited its influence with these groups.

State Department officials traveling with Mr. Kerry declined to discuss whether the United States would soon be prepared to take that step.

President Obama rebuffed a proposal last year from the State Department, the Pentagon and the C.I.A. that the United States arm and train a cadre of opposition fighters.

With the violence escalating, Aleppo under attack by Scud missiles and members of a quarrelsome Syrian opposition challenging the value of the Rome meeting — which was supposed to be a highlight of Mr. Kerry’s trip — the State Department issued a statement on Saturday evening that condemned the rocket attacks “in the strongest possible terms” and prodded the Syrian opposition to attend the session.

The statement continued, “We look forward to meeting soon with the leadership of the legitimate representative of the Syrian people, the Syrian Opposition Coalition, to discuss how the United States and other friends of the Syrian people can do more to help the Syrian people achieve the political transition that they demand and that they deserve.”

Read More..

Channing Tatum & Jenna Dewan-Tatum Show Off Baby Bump at Oscars

By Maggie Coughlan

02/24/2013 at 06:45 PM EST

Channing Tatum and Jenna Dewan-Tatum

Jason Merritt/Getty

Who is your bump wearing?

Parents-to-be Channing Tatum and Jenna Dewan-Tatum brought a very special guest to Sunday night's 85th Annual Academy Awards – wearing a black lace, backless dress, Dewan-Tatum, 32, showed off her new curves, while husband Tatum revealed where their baby will be born.

"I'm walking the carpet, trying to keep it together tonight but we're good!" a radiant Dewan-Tatum told Ryan Seacrest on the red carpet Sunday night.

When asked by Seacrest if the couple had any plans to slow down for some "family time," Tatum, 32, replied: "We're gonna actually have the baby in London while I'm shooting so there will be no downtime whatsoever after that."

Tatum – who was named PEOPLE's 2012 Sexiest Man Alive – recently told PEOPLE that he's doing his homework before the baby arrives.

"I have never changed a diaper before, so I may need some help learning," the actor said at the time. "I don't have friends who have kids, so it's going to be an interesting experience to learn how to change a diaper."

The couple's first child is due this summer.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Asian shares edge higher, yen falls on BOJ report

TOKYO (Reuters) - Asian shares edged higher on Monday, with investors still picking up shares battered by last week's steep plunge, while the yen fell to fresh lows on news a reflationary advocate could head the Bank of Japan next month.

The news Japan's government is likely to nominate Asian Development Bank President Haruhiko Kuroda, an advocate of aggressive monetary easing, as its next central bank governor, is set to be a major factor in financial markets this week.

Markets are pondering whether Italy's weekend elections will produce a stable government, and the implications of that for euro zone cohesion, while Moody's credit downgrade on Britain will play on confidence in the pound and government bonds.

Investors also await testimony on Tuesday from Fed Chairman Ben Bernanke for further clues of when the Fed may slow or stop buying bonds. Financial markets were rattled last week after minutes of the Fed's January meeting suggested some Fed officials were mulling scaling back its strong monetary stimulus earlier than expected.

The MSCI's broadest index of Asia-Pacific shares outside Japan <.miapj0000pus> was up 0.1 percent, pulled higher by Australian shares <.axjo> which gained 0.6 percent on reassuring comments from U.S. Federal Reserve officials on the bank's current stimulus program, which has helped underpin risk sentiment globally.

South Korean shares <.ks11> opened up 0.2 percent, with the nation's new leader, who has shown willingness to talk down the won, being sworn in on Monday.

Tokyo's Nikkei stock average <.n225> opened 1.6 percent higher. <.t/>

Early on Monday, the yen touched its lowest since May 2010 of 94.61 yen against the dollar, while the euro rose to a high of 124.83 yen, still off its 34-month peak of 127.71 set early this month.

The Nikkei newspaper reported the Japanese government is likely to nominate Haruhiko Kuroda and Kikuo Iwata, both vocal advocates of aggressive monetary expansion, as BOJ governor and deputy governor.

The dollar fell sharply to below 93 yen last week on media reports that Toshiro Muto, a former financial bureaucrat perceived as less willing to take unconventional steps, was the frontrunner candidate for the top BOJ job.

"The dollar's move this morning is merely a rebound from disappointment on Muto last week. I don't think this topic will be enough to hoist the dollar above 95 yen," said Hiroshi Maeba, head of FX trading Japan at UBS in Tokyo. "No matter who is elected at the BOJ, it will not affect the longer-term trend of a weak yen," he said.

Speculation over the BOJ has been a key factor driving the yen lower recently due to anticipation for strong reflationary measures, but other fundamental factors such as Japan's deteriorating trade balances and signs of firmer U.S. growth also supported a weakening yen trend.

Abe told Americans on Friday "I am back and so is Japan" and vowed to get the world's third biggest economy growing again.

Investors remained cautious before the full official results of Italy's elections come out on Tuesday, worried a potential political stalemate could impede Rome's progress on fiscal reforms.

The euro was up 0.1 percent to $1.3192, off Friday's six-week low of $1.31445.

Sterling fell to a 31-month low of $1.5073 early on Monday and a record low against the New Zealand dollar at NZ$1.8025 following Friday's one-notch downgrade of Britain's prized triple-A sovereign rating by Moody's.

Investors will also seek signs of recovery from the flash estimate of China's manufacturing PMI from HSBC/Markit due later in the session.

Wall Street ended higher on Friday, boosted strong earnings from Dow component Hewlett-Packard , but the benchmark Standard & Poor's Index <.spx> posted its first weekly decline of the year. European shares rose on Friday after data showed German business morale surged at its fastest pace in over two years in February.

Hedge funds and other big speculators cut their bullish bets on U.S. commodities by nearly $13 billion, the most in about 10 months, in the week to February 19 to $69 billion, just before oil and metals prices tumbled last week on rumors a commodities fund was dumping positions, trade data showed on Friday.

U.S. crude was up 0.1 percent to $93.26 a barrel.

(Editing by Eric Meijer)

Read More..

Syrian Flood Into Lebanon Stirs Fear of Looming Disaster

QAA, Lebanon — Quietly but inexorably, a human tide has crept into Lebanon, Syria’s smallest and most vulnerable neighbor.

As Syrians fleeing civil war pour over the border, the village priest here, Elian Nasrallah, trudges through muddy fields to deliver blankets. His family runs a medical clinic for refugees. When Christian villagers fret about the flood of Sunni Muslims, he replies that welcoming them is “the real Christianity.”

But the priest and his parishioners cannot keep up. The United Nations counts more than 305,000 Syrian refugees in Lebanon, but local officials and aid workers say the actual number is about 400,000, saturating this country of four million.

The Lebanese government — by design — has largely left them to fend for themselves. Deeply divided over Syria, haunted by memories of an explosive refugee crisis a generation ago, it has mostly ignored the problem, dumping it on overwhelmed communities like Qaa.

So far, Lebanon’s delicate balance has persevered, but there is a growing sense of emergency.

Sectarian tensions are rising. Fugitive Syrian rebels in border villages have clashed with Lebanese soldiers. The government’s anemic response has delayed international aid. Local volunteers are running out of cash and patience.

And the battle for Damascus, Syria’s capital, has barely begun. Should fighting overwhelm that religiously and politically mixed city of 2.5 million a half-hour drive from Lebanon, the Lebanese fear a cataclysm that could sweep away their tenuous calm.

“There is a limit to what the country can handle,” said Nadim Shubassi, mayor of Saidnayel, a Sunni town now packed with Syrians. “Maybe we have reached this limit now.”

Lebanon’s refugee crisis does not match the familiar image of vast, centralized tent camps and armies of foreign aid organizations. It is nowhere, and everywhere. Displaced Syrians seem to fill every nook and cranny: half-finished cinder block houses, stables, crowded apartments.

It is easy to miss them, until a second glance. Drying laundry peeks from construction sites. Bedsheets hang in shop windows, concealing stark living spaces. Daffodil sellers, shoeshine men, women and children begging in Beirut — all incant, “Min Suria.” From Syria.

At first, most refugees — mainly Sunnis, like most of the rebels fighting Syria’s government — headed for friendly Sunni areas. Now, those communities are swamped and resentful, and Syrians are spreading to places where they fit less comfortably, from Christian mountain villages to the Mediterranean city of Tyre in the southern Shiite Muslim heartland.

They are moving, with some trepidation, into Qaa, in the northern Bekaa Valley, the territory of the powerful Shiite militia Hezbollah, which is allied with Syria’s government and, to many refugees, just as fearsome.

As they flee increasingly sectarian killing, Syrians layer their fears onto those of a country deeply scarred by its own generation-long sectarian civil war. They are testing, yet also relying on, the fragile yet flexible balance that has endured here, punctured by occasional fighting, since Lebanon’s war ended 22 years ago.

In Baalbek, a Hezbollah stronghold where a poster of the Syrian president, Bashar al-Assad, grins down on a busy street, refugees turn to Sawa, a community group that views helping them as embodying its nonsectarian mission. Still, they rattle Abbas Othman, a Sawa member.

“We are worried they will bring their civil war here,” he said.

One recent evening in Qaa, Mr. Nasrallah, the priest, stood outside a burlap shack that sheltering a Syrian family of 12. They clamored around him; they had eaten only potatoes that day. Cold crept in as a blue dusk fell. One man implored, “You are responsible for us!”

The priest threw up his hands.

“It’s wartime,” he said. “Is the government doing its job or not?”

Lebanese decision-makers wanted it this way, at first. A year ago, just 5,000 Syrians had fled here, and Hezbollah, Lebanon’s most powerful political party, denied any sense of crisis.

Reporting was contributed by Hwaida Saad, Hania Mourtada, Ben Solomon and Lynsey Addario.

Read More..

Predict the Oscar Winners!

• Facebook


• Tweet

• Facebook


• Tweet

Cast your vote for who will be the night's big winners Click here to download a printable ballot.

Click here to download a printable ballot.

Polls
completed:

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.

Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.

Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.

"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.

Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.

But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.

National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.

"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.

OPTIONS BULLS TARGET GAINS

The spending cuts, if they go ahead, could hit the defense industry particularly hard.

Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.

Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.

"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.

The stock ended up 0.6 percent at $88.12 on Friday.

If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.

General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.

EYES ON GDP DATA, APPLE

The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.

U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.

Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.

Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.

On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.

(Additional reporting by Doris Frankel; Editing by Kenneth Barry)

Read More..

The Saturday Profile: Pavel Astakhov: The Man Behind U.S. Adoption Ban

Mikhail Metzel/Associated Press

Pavel A. Astakhov at a news conference in Moscow last month.

MOSCOW — Long before joining the federal government as Russia’s child rights commissioner and, more recently, becoming the leading force behind a ban on the adoption of Russian children by Americans, Pavel A. Astakhov transformed himself into a celebrity lawyer with mass market appeal — no small trick in a country where encounters with the legal system are as desirable as a tooth extraction.

There was “The Hour of Trial with Pavel Astakhov,” a courtroom reality television show casting him as Russia’s Judge Judy along with a radio program of the same name. There was a second radio program called “Advocacy Defense Techniques of Pavel Astakhov”; a series of books titled “Your Attorney: Pavel Astakhov,” with installments on housing, property rights, inheritance, pensions and family law; several legal-thriller novels fashioned in the tradition of John Grisham; a seminar series called “Pavel Astakhov’s School of Advocacy Skills”; and a law firm named the Pavel Astakhov Moscow City Law Bar.

The law banning adoptions by Americans was not named after him, but it might as well have been.

In the weeks before and after the law was approved by Parliament and signed by President Vladimir V. Putin, Mr. Astakhov was its loudest and most visible champion, insisting that Russia take care of its own orphans and not sell them to foreigners.

And it was Mr. Astakhov who this week stoked a furor over the latest death of an adopted Russian child in the United States, Max Shatto, with a post on Twitter that said: “Urgent! In the state of Texas, an adoptive mother killed a 3-year-old Russian child.”

Investigators say the circumstances of that death remain murky, and Mr. Astakhov has backed away from the murder accusation — but only slightly. At a news conference, he equated the boy’s mother, Laura Shatto, with two adoptive fathers, Miles Harrison of Virginia and Brian Dykstra of Iowa, who were acquitted of killing their toddler sons.

“Well, the presumption of innocence, you know how it is — sometimes it becomes so rigid,” Mr. Astakhov said.

Referring to the acquittals of Mr. Harrison and Mr. Dykstra, he declared, “For everyone it was completely clear that in one way or another they were guilty for the deaths of their children.”

In frequent television appearances, Mr. Astakhov denounces international adoptions in general as a sinister, profit-driven business, and he is pushing to extend the ban to all countries. He has been advocating that since 2010 after a woman in Tennessee put her 7-year-old adopted son on a flight back to Russia alone, with a note saying, “I no longer wish to parent this child.”

THIN, impeccably dressed and telegenically handsome with perfectly coifed hair that occasionally glints with an unnatural shade of bronze, Mr. Astakhov delivers nearly every statement that he makes with the silver-tongued flair of a courtroom closing argument.

“Don’t present me as an America-hater,” Mr. Astakhov, who holds a Master of Laws degree from the University of Pittsburgh, said after a recent news conference. “I am a fighter for the rights of Russian children. I am fighting with those who violate children’s rights.”

He added: “I am only saying that it’s a shame that Russia is giving away its children. America does not give away its children, does it?”

But he also often peppers his remarks with references to abusive American parents who he says have mostly escaped proper punishment, calling them “bastards” and “pedophiles.”

In response to his aggressive promotion of the ban, critics have denigrated his nationalist statements as hypocrisy, noting that the eldest of Mr. Astakhov’s three biological children attended private schools in England and the United States, while the youngest was born in 2009 in the same private hospital in Nice, France, where Angelina Jolie gave birth to twins.

A magazine spread showed Mr. Astakhov; his wife, Svetlana; and their children posing in luxurious surroundings in France where they spend the summers, and in an accompanying article he marveled at the prenatal care that his wife received, saying that while pricey it was still cheaper than elite maternity hospitals in Russia.

Read More..

Danica Patrick Opens Up About Dating Competitor Ricky Stenhouse, Jr.

By Dahvi Shira

02/22/2013 at 07:25 PM EST

Danica Patrick and Ricky Stenhouse Jr.

Tom Pennington/NASCAR/Getty

Danica Patrick knows mixing business with pleasure isn't wise, but it's not stopping her.

"I don't think it was a good idea. [But] there was nothing I could do about it," she tells menshealth.com of getting into a relationship with fellow NASCAR racer, Ricky Stenhouse, Jr., 25. "You can't tell your heart who to like and not like. It just happened."

Patrick, 30, isn't worried about running into a future ex-boyfriend on the racetrack.

"I know I'm setting myself up for that," she says with a laugh. "But I choose not think about that possibility right now. I'm going to be positive."

For now, the competition is friendly between the history-making superstar – who announced her split from husband Paul Hospenthal in November – and her new beau.

"Ricky and I have always had that situation where we give each other room [on the track]," Patrick says. "We respect each other on the track. I don't see any reason for that to change."

But despite the relationship, business is still business, and if something happened to her man mid-competition, she'd leave his care to handlers and continue on with the race.

"We both understand that this is a dangerous sport," she says. "We know that things will happen, and we have faith in the safety of the cars and the tracks and the medical staff. If something did happen to him, there's nothing I could do to help. I'd just have to remember that everything that needed to be done to make him safe was being done."

Patrick, meanwhile, is set for the coveted pole position for her second turn in the Daytona 500 Sunday.

Read More..